United States: US Courts Issue Helpful Decisions In Two Cases Involving Admissibility Of Expert Testimony On Specific Causation

Keywords: General, specific, causation, gas odor

A plaintiff claiming harm from exposure to a substance generally must prove both general and specific causation. General causation requires proof that the substance can cause the type of harm that the plaintiff suffered. It is most commonly established through epidemiological studies demonstrating a causal connection between exposure to the substance and the particular disease or injury in question. Specific causation requires proof that the harm claimed by the particular plaintiff was caused by the exposure that he or she attributes to the defendant. It requires a fact-specific analysis of the plaintiff's claim, including the nature of the exposure, the nature of the harm claimed by the plaintiff, and other possible causes of that harm.

For many substances that are the subject of litigation, an existing body of literature establishing the effects of exposure supports general causation. Accordingly, in many exposure cases—including environmental torts, workplace exposures, and products liability—the real hurdle a plaintiff must clear in order to reach the jury (at least with respect to questions of causation) is producing admissible evidence of specific causation. Two recent decisions demonstrate different ways in which such testimony can fail the test of admissibility, likely spelling doom for the plaintiff's claim.

1.Sean R. v. BMW of N. Am., LLC1

Plaintiffs who allege exposure to a toxic substance often have a difficult time proving the extent of their exposure. Unless there is historical testing available, or the exposure is ongoing and, thus, can be measured for purposes of litigation, plaintiffs often must attempt to estimate their exposure by analogy to available studies in other contexts or by more creative means. Such estimation methods, like all aspects of opinion testimony, are subject to the admissibility standards for expert testimony in the relevant jurisdiction.

Plaintiffs faced with a challenge to the admissibility of their exposure estimate often argue, or at least imply, that the court should relax the standards for admissibility in light of the practical difficulties they face in estimating a past exposure. In a recent decision, the New York Court of Appeals—New York's highest court—rejected such an exhortation and confirmed that methods used to estimate exposures are subject to the same admissibility requirements as any other opinion testimony.

In Sean R., the plaintiff alleged that he suffered severe birth defects due to in utero exposure to gas fumes in his parents' automobile. The plaintiff's family had complained of a gas odor in the vehicle and reported symptoms such as nausea, dizziness, and headaches when riding in the vehicle. Eventually, the vehicle was found to have a split fuel line that was leaking gasoline into the engine compartment.

In order to show that the resulting exposure to the plaintiff's mother was sufficient to cause the plaintiff's birth defects, the plaintiff's experts used a "symptom threshold" methodology. Studies show that people first experience certain symptoms from exposure to gasoline fumes at particular concentration levels. Because the plaintiff's family had reported those symptoms, the expert inferred that the exposure level must have met the threshold in the studies.

The trial court sustained the defendant's objection to this methodology and the Court of Appeals affirmed. The Court of Appeals began by observing that "[a]lthough it is not always necessary for a plaintiff to quantify exposure levels precisely, we have never dispensed with a plaintiff's burden to establish sufficient exposure to a substance to cause the claimed adverse health effect." Because New York uses the Frye standard for admissibility of expert testimony, the court then asked whether the methods used by the plaintiff's experts "when properly performed, generate results accepted as reliable within the scientific community generally."

The court noted that a similar methodology—using "odor thresholds" to infer an exposure level based on the concentration at which the substance is first capable of olfactory detection—appears to be generally accepted as reliable. It pointed out, however, that the plaintiff had not identified "any text, scholarly article or scientific study ... that approves of or applies [symptom thresholds to determine concentrations], let alone a 'consensus' as to [that method's] reliability." Accordingly, the court affirmed the exclusion of the expert testimony, which will likely result in judgment for the defendant based on the plaintiff's inability to prove specific causation.

Sean R. demonstrates an admirable commitment to rigorous enforcement of the principles that control the admission of expert testimony in a courtroom. The outcome could be different, however, in jurisdictions that have abandoned the Frye standard in favor of the Daubert test. Under Daubert, the touchstone is reliability, and general acceptance is only one factor to be considered in determining whether the methodology in question is reliable. Other reliability factors could well cause a court to conclude that using "symptom thresholds" to estimate concentration levels is sufficiently reliable to allow the testimony to go to the jury.

2.In re: Lipitor (Atovastatin Calcium) Marketing, Sales Practices & Prods. Liab. Litig.2

It is easy for courts to fall into the trap of thinking that general causation plus a temporal relationship between exposure and injury equals specific causation. When there is scientific evidence that exposure to a substance can cause a type of injury, the plaintiff was exposed to that substance, and the plaintiff then suffered that type of injury, it is tempting to allow expert testimony attributing the injury to the exposure without further support or analysis. A recent decision of the District of South Carolina in the multi-district litigation (MDL) involving the drug Lipitor rejects such fallacious reasoning.

The plaintiffs in the Lipitor MDL allege that their Type 2 diabetes was caused by the cholesterol drug Lipitor. In considering a challenge to the specific-causation testimony in a bellwether trial, the court observed that the plaintiff developed diabetes after taking Lipitor and that there are epidemiological studies finding a causal connection between Lipitor and diabetes. Those studies, however, establish a "relative risk ratio" between Lipitor and diabetes of approximately 1.6.

"The relative risk ratio is the risk of disease or injury among people exposed to an allegedly harmful substance divided by the risk of the disease among those not exposed to the substance." In other words, the risk that someone taking Lipitor will develop diabetes is 1.6 times higher than the risk for a similarly situated person who is not taking Lipitor. This means, however, that almost two-thirds of people who develop diabetes while taking Lipitor would have developed the disease anyway. Indeed, for any relative risk ratio below 2.0, more than half of the people who are injured following exposure would have suffered the injury anyway. "[T]he question then becomes how does [the plaintiff's expert] conclude that [the plaintiff] is in the 37% that develop diabetes due to Lipitor, rather than the 63% that would have done so regardless."

On this point, the plaintiff's expert "exclusive[ly] reli[ed] on a temporal relationship" between taking Lipitor and developing diabetes and "was unable to point to a single piece of evidence that she found in [the plaintiff's] medical files ... that would affect her assessment of whether Lipitor caused the patient's diabetes." The expert conceded that the plaintiff had numerous other risk factors for diabetes, some of which had relative risk ratios as high as 12.0. As the court explained, however, "[s]imply because a person takes a drug and then suffers an injury does not show causation. Drawing such a conclusion from temporal relationships leads to the blunder of the post hoc ergo propter hoc fallacy."

The court further reasoned that the expert could not "simply opine that all present risk factors are 'substantial contributing factors.' Risk factors are potential causes of diabetes. Identifying potential causes is the work of general causation and, without more, does not suffice for a specific causation opinion."

Finally, the expert could not clear the hurdle of admissibility by claiming that she performed a differential etiology because that method "must be reliably applied," and the opinions of an expert who purports to rely on such a methodology "must be supported by sufficient facts and data." Here, the expert offered no reliable explanation for attributing this plaintiff's diabetes to Lipitor, a failing that was all the more problematic because the plaintiff had many significant risk factors for diabetes independent of the use of Lipitor. Accordingly, the district court excluded the expert's testimony, leaving the bellwether plaintiff with no evidence on a critical element of her claim.

While Lipitor is a well-reasoned decision, its utility may be limited. The opinion notes that general causation plus a temporal relationship alone may be enough to prove specific causation in cases where the relative risk ratio is greater than 2.0. In such cases, more than half of those who develop a disease or injury following exposure would not have developed that disease or injury but for the exposure, which some courts have concluded is sufficient to satisfy the plaintiff's burden to prove specific causation by a preponderance of the evidence. There may be valid grounds for challenging the relative risk ratio identified by the plaintiff in such cases, but when the risk ratio is contended to be greater than 2.0 the Lipitor decision may change from an asset to a liability.


1 2016 WL 527107 (N.Y. Feb. 11, 2016).
2015 WL 9165589 (D. S.C. Dec. 11, 2015).

Originally published on 25 February 2016

Visit us at mayerbrown.com

Mayer Brown is a global legal services provider comprising legal practices that are separate entities (the "Mayer Brown Practices"). The Mayer Brown Practices are: Mayer Brown LLP and Mayer Brown Europe – Brussels LLP, both limited liability partnerships established in Illinois USA; Mayer Brown International LLP, a limited liability partnership incorporated in England and Wales (authorized and regulated by the Solicitors Regulation Authority and registered in England and Wales number OC 303359); Mayer Brown, a SELAS established in France; Mayer Brown JSM, a Hong Kong partnership and its associated entities in Asia; and Tauil & Chequer Advogados, a Brazilian law partnership with which Mayer Brown is associated. "Mayer Brown" and the Mayer Brown logo are the trademarks of the Mayer Brown Practices in their respective jurisdictions.

© Copyright 2016. The Mayer Brown Practices. All rights reserved.

This Mayer Brown article provides information and comments on legal issues and developments of interest. The foregoing is not a comprehensive treatment of the subject matter covered and is not intended to provide legal advice. Readers should seek specific legal advice before taking any action with respect to the matters discussed herein.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.